No per-APS about it.
EpicentRx is a definite for the American Physiology Summit (APS) from April 4-7 in Long Beach, California where the UCSD bioengineering lab of Dr. Pedro Cabrales will present 3 posters on its lead small molecule, RRx-001 (nibrozetone).
The titles and dates of these poster sessions are as follows:
1) ABSTRACT ID/ABSTRACT TITLE: 629/Preventing kidney failure in hemolytic anemias with a novel heme and hemoglobin scavenger
POSTER SESSION TITLE: Immunology and Microbiology of the Gut Poster Session
POSTER PRESENTATION DAY: Thursday, April 4, 2024
2) ABSTRACT ID/ABSTRACT TITLE: 1336/Unlocking Therapeutic Potential: RRx-001 Mitigates Atherosclerosis via Nrf2-Mediated ROS/TXNIP/NLRP3 Pathway
POSTER SESSION TITLE: Cardiovascular Physiology
POSTER PRESENTATION DAY: Friday, April 5, 2024
3) ABSTRACT ID/ABSTRACT TITLE: 1609/RRx-001 protects from diabetic nephropathy
POSTER SESSION TITLE: Acute Kidney Injury: Mechanisms, Treatment and Associated Pathology
POSTER PRESENTATION DAY: Saturday, April 6, 2024
These posters highlight the breadth and depth of RRx-001 (nibrozetone) as a late-stage anticancer agent with the potential to also reduce inflammation-induced renal and cardiovascular injury. RRx-001 has demonstrated broad protective effects in several disease models, including oral mucositis, neurological and metabolic disorders, endometriosis, heart, lung, and kidney disease, and kidney transplantation.
RRx-001 protects normal tissues and organs through inhibition of the NLRP3 inflammasome, a collection of proteins that kickstarts and maintains the inflammatory process, induction of the master antioxidant transcription factor, Nrf2, and release of the vasodilator, nitric oxide (NO), only under poorly oxygenated or ischemic conditions.
So, RSVP both “yes” and “NO”, NO for nitric oxide, and, hopefully, we’ll see you there.